It has previously been reported that cardamonin is able to regulate glycometabolism and vasodilation whilst also exhibiting anti‑inflammatory and antitumor properties. The antitumor effect of cardamonin is multifaceted, and so it is necessary to investigate the antitumor mechanisms of cardamonin at the molecular level. Cardamonin alters chemotherapy‑resistant colon cancer cell growth; however, the underlying mechanism is unknown. The present study was conducted to investigate the effect of cardamonin on chemotherapy‑resistant colon cancer cells and the possible mechanisms of action. Cardamonin significantly suppressed the growth of chemotherapy‑resistant colon cancer cells, induced apoptosis and promoted caspase‑3/9 activity and Bax protein expression in 5‑fluorouracil (5‑FU)‑resistant HCT‑116 cells. Cardamonin significantly suppressed c‑MYC, octamer‑binding transcription factor 4, cyclin E, testes‑specific protease 50 and nuclear factor‑κB protein expression in 5‑FU‑resistant HCT‑116 cells. The findings of the present study demonstrate that cardamonin suppresses chemotherapy‑colon cancer cell via the NF‑κB pathway in vitro.
Background: Gastrointestinal stromal tumor (GIST) is a common tumor that originates from the alimentary system mesenchyme. Compared to typical gastrointestinal carcinomas, GISTs exhibit unique malignant behaviors. Bioinformatic tools and subsequent experiments were applied to investigate novel targets involved in GIST progression and imatinib resistance. Methods: Differences in gene expression profiles between advanced and nonadvanced GISTs were comprehensively analyzed based on the Gene Expression Omnibus (GEO) dataset GSE136755. A protein–protein interaction (PPI) network was constructed to identify the potential target gene. Gene set enrichment analysis (GSEA) was used to elucidate relevant biological events related to the target gene based on the GSE47911 dataset. Subsequently, immunohistochemistry and Kaplan–Meier analysis were performed to validate the prognostic value of the target gene in GISTs. Overexpression of the target gene was conducted to analyze its function in the proliferation, apoptosis, and imatinib resistance of GIST/T1 cells. Results: In the current study, a total of 606 differentially expressed genes (DEGs) were screened based on the GSE136755 dataset, and the upregulated DEGs in advanced GISTs were mainly involved in cell division through functional annotations. The intersecting hub gene, Aurora kinase A (AURKA), was identified by degree and bottleneck algorithms. GSEA revealed that AURKA was involved in cell cycle-related biological processes. Analysis of the Oncomine and GEPIA databases revealed a pattern of elevated AURKA expression in most human malignances. Clinical assays demonstrated that AURKA could be an independent prognostic factor for GISTs. Additionally, overexpression of AURKA was experimentally demonstrated to promote cell proliferation, inhibit cell apoptosis, and enhance imatinib resistance in GIST/T1 cells. Conclusions: These findings indicated that overexpression of AURKA promoted GIST progression and enhanced imatinib resistance, implying that AURKA is a potential therapeutic target for GISTs.
Objectives: The prognostic value of age at diagnosis in colon cancer is poorly understood. This study evaluated the influence of age at diagnosis and histologic subtype on colon cancer prognosis using data from 180,804 patients in the SEER database. Methods: Patients were stratified into early‐onset and late‐onset groups and by histology—adenocarcinoma or mucinous adenocarcinoma. Early‐onset colon cancer was associated with more advanced tumor stages. Propensity score matching balanced cohorts for Kaplan–Meier and Cox regression analyses of cancer‐specific survival (CSS) and surgery‐specific survival (SSS). Results: Survival analyses revealed that patients with early‐onset adenocarcinoma had the most favorable CSS and SSS, whereas those with late‐onset mucinous adenocarcinoma experienced the worst outcomes; no significant age‐related differences emerged histology‐stratified. Importantly, among nonmetastatic patients, early‐onset adenocarcinoma showed significantly poorer SSS compared to late‐onset adenocarcinoma. Conclusion: These findings emphasize the necessity of integrating age and histologic type for accurate prognostic assessment and personalized treatment strategies in colon cancer.
26 June 2026 in Cellular and Molecular Life Sciences
Background: Gastrointestinal stromal tumor (GIST) is a common tumor that originates from mesenchyme in the alimentary system. Compared to the typical gastrointestinal carcinomas, GISTs exhibit unique malignant behaviors. Bioinformatic tools and subsequent experiments were applied to investigate novel targets involved in GIST progression and imatinib resistance. Methods: Differences of gene expression profiles between advanced and non-advanced GISTs were comprehensively analyzed based on Gene Expression Omnibus (GEO) dataset GSE136755. A protein-protein interaction (PPI) network was conducted to identify the potential target gene. Gene set enrichment analysis (GSEA) was used to elucidate relevant biological events of the target gene based on dataset GSE47911. Subsequently, immunohistochemistry and Kaplan-Meier analysis were performed to validate the prognostic value of the target gene in GISTs. Overexpression of the target gene was conducted to analyze its functions in proliferation, apoptosis, migration, and imatinib resistance of GIST/T1 cells. Results: In current study, a total of 606 differentailly expressed genes (DEGs) were screened based on dataset GSE136755 and the upregulated DEGs in advanced GISTs were mainly involved in cell division through functional annotations. The intersected hub gene, Aurora Kinase A (AURKA), was identified by degree and bottleneck algorithms. GSEA revealed that AURKA was involved in cell cycle-related biological processes. Oncomine and GEPIA databases supported an elevated expression pattern of AURKA in most human malignances. Clinical assay demonstrated that AURKA could be an independent prognostic factor for GISTs. Additionally, overexpression of AURKA was experimentally demonstrated to promote cell proliferation and survival, and enhance imatinib resistance of GIST/T1 cells. Conclusions: These findings indicated that overexpression of AURKA promoted GIST progression and enhanced imatinib resistance, implying the potential of AURKA as a therapeutic target for GISTs.